Display options
Cite
Tahir M, Bashir U, Hafeez J, et al. Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan. Pak J Med Sci. 2019;35(2):495-499doi: 10.12669/pjms.35.2.54.
Tahir, M., Bashir, U., Hafeez, J., & Ghafoor, R. (2019). Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan. Pakistan journal of medical sciences, 35(2), 495-499. https://doi.org/10.12669/pjms.35.2.54
Tahir, Moizza, et al. "Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan." Pakistan journal of medical sciences vol. 35,2 (2019): 495-499. doi: https://doi.org/10.12669/pjms.35.2.54
Tahir M, Bashir U, Hafeez J, Ghafoor R. Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan. Pak J Med Sci. 2019 Mar-Apr;35(2):495-499. doi: 10.12669/pjms.35.2.54. PMID: 31086539; PMCID: PMC6500830.
Copy Download .nbib Format: NLM
Share it on

Pak J Med Sci. 2019 Mar-Apr;35(2):495-499. doi: 10.12669/pjms.35.2.54.

Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan.

Pakistan journal of medical sciences

Moizza Tahir, Uzma Bashir, Javeria Hafeez, Rabia Ghafoor

Affiliations

  1. Dr. Moizza Tahir, MCPS (Med), FCPS (Derm), MHPE, Associate Professor, Department of Dermatology, Combined Military Hospital/CMH Institute of Medical Sciences, Multan, Pakistan.
  2. Dr. Uzma Bashir, MCPS(Med), FCPS(Derm), Assistant Professor of Dermatology, Combined Military Hospital/Quetta Institute of Medical Sciences, Quetta, Pakistan.
  3. Dr. Javeria Hafeez, MCPS(Med), FCPS(Derm), Assistant Professor of Dermatology Combined Military Hospital, Bhawalpur, Pakistan.
  4. Dr. Rabia Ghafoor, FCPS(Derm), SCE(UK), Assistant Professor of Dermatology, Jinnah Post Graduate of Medical Sciences, Karachi, Pakistan.

PMID: 31086539 PMCID: PMC6500830 DOI: 10.12669/pjms.35.2.54

Abstract

BACKGROUND & OBJECTIVE: Cutaneous Leishmaniasis (CL) is endemic in Baluchistan and treated traditionally with Meglumine antimoniate. Miltefosine appears appealing therapy in cutaneous Leishmaniasis. Our objective was to evaluate safety and efficacy of Miltifossine in treatment of cutaneous Leishmaniasis.

METHODS: This experimental study was conducted from 10 September 2017 to 10 May 2018 at Combined Military Hospital Quetta. Total of 42 patients were recruited by purposive sampling technique. Lesional skin smears were stained with giemsa for Leishmania amastigotes under magnification (100 x).Complete blood count, serum urea, creatinine, bilirubin, aspartate aminotransferases (AST), alanine aminotransferase (ALT) were done at the beginning of treatment and then weekly, thereafter. Cap Miltefosine 50 mg (2.5mg/kg) were given as directly observed therapy .Daily observation during treatment phase was done for clinical side effects of therapy. Clinical response was documented at two weeks then at eight weeks. Photographs were taken before and after the therapy. Data was analyzed by SPSS 16.

RESULTS: Complete clinical response was observed in 39 (92.9%) patients and partial clinical response in 1(2.4%) patient. Two patients were lost to follow up at eight weeks. No significant derangements in laboratory profile were noted before and after treatment. Mean duration of treatment was 23.47+SD 4.44 days. Sixteen patients (38.1%) took Miltefosine for 28 days, 12 (28.6%) for 21 days and 9 (25%) for 25 days.

CONCLUSION: Miltefosine is safe and cost effective treatment for cutaneous Leishmaniasis. It is effective in CL cases not susceptible to antimony compounds.

Keywords: Cutaneous leishmaniasis; Meglumine antimoniate; Miltefosine

References

  1. J Coll Physicians Surg Pak. 2007 Mar;17(3):132-5 - PubMed
  2. Dermatol Online J. 2012 Feb 15;18(2):4 - PubMed
  3. Am J Trop Med Hyg. 2012 Mar;86(3):434-40 - PubMed
  4. J Antimicrob Chemother. 2012 Nov;67(11):2576-97 - PubMed
  5. J Family Community Med. 2009 May;16(2):41-7 - PubMed
  6. Korean J Parasitol. 2013 Feb;51(1):75-84 - PubMed
  7. PLoS One. 2014 Jun 18;9(6):e100220 - PubMed
  8. Expert Opin Biol Ther. 2014 Nov;14(11):1641-9 - PubMed
  9. J Dermatolog Treat. 2016;27(1):83-7 - PubMed
  10. Nat Rev Immunol. 2016 Sep;16(9):581-92 - PubMed
  11. Am J Trop Med Hyg. 2017 Jan 11;96(1):24-45 - PubMed
  12. Trop Med Int Health. 2018 Jun;23(6):622-633 - PubMed
  13. Mem Inst Oswaldo Cruz. 2018 Jun 21;113(9):e180200 - PubMed
  14. Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):430-439 - PubMed
  15. J Pak Med Assoc. 1986 Jun;36(6):134-8 - PubMed

Publication Types